Wire · opportunities
FDA Grants Accelerated Approval to a New Breast Cancer Treatment
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 September 2026 · Fusion42 review
The FDA granted accelerated approval to Etcamah (camizestrant), combined with a CDK4/6 inhibitor, for adult patients with HR-positive, HER2-negative advanced breast cancer showing ESR1 mutation detected by a blood test. This marks the first approval based on detecting a resistance mutation in circulating tumor DNA before disease progression by imaging.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now access a new approved breast cancer treatment targeting ESR1 resistance mutations detected earlier via blood tests. This opens fresh patient targeting before visible disease progression, creating new clinical timing and diagnostic possibilities for your oncology startups.
◆ Coverage
1 source · 4 Sep 2026
◆ Related on Wire
◆ Topics